Vera Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On 05 de nov. de 2025, VERA reported earnings of -1.26 USD per share (EPS) for Q3 25, missing the estimate of -1.15 USD, resulting in a -8.76% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.03% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analistas forecast an EPS of -1.30 USD, with revenue projected to reach -- USD, implying an aumentar of 3.17% EPS, and aumentar of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Vera Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Vera Therapeutics, Inc. Class A Common Stock reported EPS of -$1.26, missing estimates by -8.76%, and revenue of $0.00, 0% as expectations.
How did the market react to Vera Therapeutics, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -1.03%, changed from $24.35 before the earnings release to $24.10 the day after.
When is Vera Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for 24 de fev. de 2026.
What are the forecasts for Vera Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 14
analistas, Vera Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.30 and revenue of -- for Q4 2025.